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ORIGINAL ARTICLE
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Background: Malignant melanoma arising from different body compartments may be associated with
differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles.
Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of
melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many
respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be
common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for
these patients. Few data are available for non-cutaneous melanomas.
Aims: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal
organs.
Methods: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS
mutation by direct DNA sequencing.
Results: BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the
aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined
mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in
malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n =6), but
was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations
in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas.
Conclusion: Each melanoma subtype may have a unique oncogenetic pathway of tumour development,
and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.
M
elanoma arises from the malignant transformation
of pigment producing cells, the melanocytes.
Melanocytes originate in the neural crest and migrate
to the basal layer of the epidermis and the hair follicles
during embryogenesis. Apart from the skin, melanocytes are
also found in most squamous covered mucous membranes,
the uveal tract in the eye, and the leptomeninges of the brain.
Thus, malignant melanomas can be classified by their site
of origin into cutaneous melanoma, mucosal melanoma,
uveal (ocular) melanoma, and leptomeningeal melanoma.
Interestingly, malignant melanoma can also arise in sites not
known to harbour melanocytes. The most prominent
example includes malignant melanoma of soft parts, also
known as clear cell sarcoma of tendons and aponeuroses.
This tumour is characterised by nests of malignant cells with
a morphological and immunohistochemical profile of mela-
nocytic differentiation, arising in tendons or aponeuroses in
the extremities of young adults. Despite a common neural
crest origin, the different subtypes of melanoma are distinct
in their age of onset, aetiology, and biological behaviour. For
example, cutaneous melanoma and malignant melanoma of
soft parts tend to have an earlier age of onset compared with
the other groups. Uveal melanoma tends to spread via the
haematogenous route, whereas cutaneous melanoma shows
a greater preference for lymphatic metastasis. Cutaneous
melanoma is by far the most common and most well studied
subtype, constituting 90% of all cases. Whereas the develop-
ment of most cutaneous melanomas is strongly linked to
exposure to ultraviolet (UV) irradiation, the aetiology of non-
cutaneous melanoma remains obscure. Moreover, melano-
mas arising from different sites may be heterogeneous in
their molecular pathway of tumour development. For
example, chromosomal aberrations such as monosomy of
chromosome 3 and gain of 8q are common in uveal but rare
in cutaneous melanoma.1 2 Conversely, alteration of the
CDKN2 locus in 9p21 is common in cutaneous but rare in
uveal melanoma.3 The t(12,22)(q13;q12) translocation,
resulting in a fusion gene product combining the 59 region
of the EWS gene and the 39 region of the ATF1 gene, is found
in 80% of malignant melanomas of soft parts, but not in other
types of melanoma.4 5 Unfortunately, because of their
relatively low incidence, genetic changes remain poorly
defined for most non-cutaneous melanomas. With the recent
development of pathway specific drug targets, defining these
genetic changes in various subtypes of melanoma may have
important therapeutic implications.
‘‘Interestingly, malignant melanoma can also arise in sites
not known to harbour melanocytes’’
It has long been known that activation of the RAS–RAF–
MEK–ERK–MAPK (mitogen activated protein kinase) path-
way plays an important role in cutaneous melanoma
development. This involves an activating mutation of
NRAS, which is found in over 20% of cutaneous melano-
mas.6–8 More recently, our group has described a high
frequency of an activating BRAF mutation (more than
60%) in melanoma cell lines and human tumour samples.9
BRAF is a serine/threonine kinase that transduces regulatory
signals from RAS through MEK to MAPK in the RAS–RAF–
MEK–ERK–MAPK signalling cascade. Subsequent studies by
Abbreviations: MAPK, mitogen activated protein kinase; PCR,
polymerase chain reaction; UV, ultraviolet
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others have confirmed these results,10–13 and have shown that
BRAF mutation is also present in a high percentage (82%) of
cutaneous melanocytic naevi.12 Over 80% of the mutations
involve a single base substitution in the kinase domain
(T1799A), leading to a V600E amino acid substitution
(nucleotide and codon numbers based on NCBI gene bank
nucleotide sequence NT_007914, corresponding to T1796A,
V599E in the old gene bank sequence NM_004333). We have
previously shown that this mutant BRAF could function in a
constitutively active form, with consequent raised kinase
activity, and could transform NIH3T3 cells.9 More recently,
several studies have indicated that in contrast to cutaneous
melanomas, BRAF mutation is rare in uveal melanomas.14–17
Three recent studies have also demonstrated a low incidence
of BRAF mutation in melanoma arising from non-hair
bearing (glabrous) skin that is relatively protected from UV
damage because of the thickened cornified layer, and in
melanoma arising from mucosa that is totally sun pro-
tected.18–20 Studies of the molecular changes in non-cuta-
neous melanomas could help to clarify their genetic pathway
of development, which may be distinct from cutaneous
melanoma. Furthermore, these results may have important
therapeutic implications because those with BRAF mutations
may benefit from specific treatment using a RAF inhibitor.
Here, we analysed a large series of non-cutaneous malignant
melanomas arising from various internal organs, including
malignant melanoma of soft parts, which has not been
studied before, for BRAF and NRAS mutations.
METHODS
Materials
We searched the computerised pathology records of the
department of pathology of Queen Mary Hospital and Queen
Elizabeth Hospital, Hong Kong from 1993 to 2003. The
clinical and pathology records of all patients with a diagnosis
of malignant melanoma or malignant melanoma of soft parts
(also named clear cell sarcoma of tendon and aponeurosis)
were retrieved for review. Patients with a diagnosis of
primary non-cutaneous malignant melanoma or metastasis
were selected for our present study. All except five cutaneous
malignant melanomas or documented metastasis from
cutaneous melanoma were excluded. The five cases of
cutaneous melanoma or distant metastasis were randomly
selected and included as controls for our mutation detection
method and potential ethnic differences because most of our
patients were of Chinese origin. This study was approved by
the ethics committee of the University of Hong Kong.
In total, 56 malignant melanomas from various organ sites
were finally selected. Table 1 lists in detail their anatomical
site of origin. The histological slides were reviewed and
appropriate paraffin wax embedded tissue blocks were
retrieved. Sections (6 mm thick) were cut and stained with
0.1% methylene blue. Areas of the malignant melanoma were
microdissected under a light microscope for DNA extraction
using standard protocols, as described previously.21
Mutation detection of BRAF and NRAS
Primers were designed to amplify exons 11 (G loop region)
and 15 (activation segment) of BRAF, and exons 1 and 2 of
NRAS. The primers for BRAF were the same as those used in
our previous study.21 The primer sequences were as follows:
N BRAF exon 11F: 59-TTCTGTTTGGCTTGACTTGACTT-39
N BRAF exon 11R: 59-ACTTGTCACAATGTCACCACATT-39
N BRAF exon 15F: 59-TCATAATGCTTGCTCTGATAGGA-39
N BRAF exon 15R: 59-GGCCAAAAATTTAATCAGTGGA-39
N NRAS exon 1F: 59- GGTTTCCAACAGGTTCTTGC-39
N NRAS exon 1R: 59- CACTGGGCCTCACCTCTATG-39
N NRAS exon 2F: 59- CACACCCCCAGGATTCTTAC-39
N NRAS exon 2R: 59- TGGCAAATACACAGAGGAAGC-39.
Polymerase chain reactions (PCRs) were performed in
20 ml reactions containing 0.5mM of each primer, 2.5mM
Mg2+, 0.25mM dNTPs, and 1 U of AmpliTaq Gold DNA
polymerase (Applied Biosystems, Foster City, California,
USA) in 16 PCR buffer. In total, 40 amplification cycles
(95 C˚ for 30 seconds, 55 C˚ for 30 seconds, and 72 C˚ for 45
seconds) were performed with an initial denaturation at 95 C˚
for 10 minutes and a final extension at 72 C˚ for 10 minutes.
The PCR products were purified with 1 ml ExoI/SAP (37 C˚ for
15 minutes, then 85 C˚ for 15 minutes) and were then
sequenced directly on both strands using the BigDyeH
Terminator v1.1 cycle sequencing kit (Applied Biosystems)
according to manufacturer’s protocol and analysed by the
Applied Biosystems 3730 DNA analyser. All mutations were
re-confirmed by independent PCR reactions and direct
sequencing.
Table 1 Mutations of BRAF and NRAS in various types of melanoma
Site
Mean age
(range)
Sample
size
No. of
mutated
BRAF (%) Nucleotide
Amino
acid
No. of
mutated
NRAS (%) Nucleotide Amino acid
Mucosal melanoma 68.1 (33–95) 36 2 (5.6) 5 (13.9)
Head and neck
Nasopharynx 13 1 (7.7) T1799A V600E 1 (7.7) G34T G12C
Maxilla 3 0 (0) 0 (0)
Hard palate or floor of mouth 4 0 (0) 1 (25) A183C Q61H
Female genital tract
Cervix 1 0 (0) 0 (0)
Vagina 4 0 (0) 1 (25) C181A Q61K
Vulva 3 1 (33.3) A1742T N581I 0 (0)
Gastrointestinal tract
Oesophagus 3 0 (0) 2 (66.7) G35A A183T G12D Q61H
Rectum 3 0 (0) 0 (0)
Anus 2 0 (0) 0 (0)
Melanoma of parenchymal organs
Brain 23 1 0 (0) 1 (100) C181A Q61K
Ovary 48 1 0 (0) 0 (0)
Malignant melanoma of soft parts 27.7 (17–38) 7 0 (0) 0 (0)
Uveal melanoma 61 (46–80) 6 0 (0) 1 (16.7) A182G Q61R
Cutaneous melanoma 55.6 (40–79) 5 2 (40) T1799A
GT1798–99AA
V600E
V600K
0 (0)
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Statistical analysis
The differences in incidence of BRAF mutations or combined
BRAF/NRAS mutations in our series of non-cutaneous
melanomas (malignant melanoma of soft parts, mucosal
melanoma, and uveal melanoma) were analysed in compar-
ison with the cumulative incidence from all major published
series of primary cutaneous malignant melanomas using
Fisher’s exact test.
RESULTS
Table 1 summarises the incidence of BRAF and NRAS
mutations in the various types of mucosal, non-cutaneous,
and cutaneous malignant melanomas. In total, there were 36
cases of mucosal melanoma, seven cases of malignant
melanoma of soft parts (clear cell sarcoma of tendon and
aponeurosis), six cases of uveal melanoma, and five cases of
cutaneous melanoma. One case of malignant melanoma
arising from melanocytes in a mature cystic teratoma of the
ovary, and one case of primary melanoma arising in the brain
associated with a focus of leptomeningeal melanosis were
also included. These cover a comprehensive spectrum of
malignant melanomas from the whole body system.
In total, two BRAF mutations were identified in the 36
malignant melanomas arising from the mucosa of the
aerodigestive and female genital tract. One mutation was
T1799A (V600E) and occurred in a malignant melanoma of
the nasopharynx. The other mutation was a novel mutation
A1742T (N581I) identified in a vulval malignant melanoma.
No BRAF mutation was identified in the seven malignant
melanomas of soft parts, six uveal melanomas, or the two
melanomas from the ovary and brain. Figure 1 shows
representative sequence chromatograms.
Five NRAS mutations were identified in the 36 mucosal
melanomas, two involving codon 12 and three involving
codon 61. These were from tumours arising from the
oesophagus (two cases), nasopharynx (one case), hard palate
(one case), or vagina (one case). Two additional NRAS
mutations were noted in a uveal melanoma and a melanoma
from the brain. None of the malignant melanomas of soft
parts harboured an NRAS mutation.
Two BRAF mutations were detected in the five cutaneous
melanomas. One mutation, T1799A (V600E), was found in
a superficial spreading type melanoma, and the other was a
tandem mutation, GT1798-99AA (V600K), occurring in a
brain metastasis from a cutaneous melanoma. The three
cutaneous melanomas without BRAF mutations were of the
acral lentiginous type, the lentigo maligna type, and a
melanoma arising from a congenital naevus. No NRAS
mutation was detected in the five cutaneous melanomas.
Overall, none of the samples that carried a BRAF mutation
had an NRAS mutation.
Table 2 summarises the statistical analysis of differences in
incidence of BRAF or combined BRAF/NRAS mutations
between the non-cutaneous melanomas from our current
series and published series of primary cutaneous melanomas.
Both the incidence of BRAF mutation and the combined
incidence of BRAF/NRAS mutations were significantly lower
in malignant melanoma of soft parts, mucosal melanoma,
uveal melanoma, and non-cutaneous melanoma as a group
compared with the cutaneous melanomas.
DISCUSSION
We have identified a BRAF mutation in two of 36 mucosal
melanomas arising from the aerodigestive and female genital
tracts. Maldonado et al previously studied 21 mucosal
melanomas and identified two BRAF mutations.20 Cohen
et al studied 25 mucosal melanomas and found one BRAF
mutation,18 whereas Edwards et al studied 13 mucosal
melanomas and found no BRAF mutations.19 Our findings
corroborate those of others that BRAF mutation is rare in
mucosal melanomas. Although one of the BRAF mutations
seen in the mucosal melanomas involved a previously
described amino acid substitution in V600 (previously
V599), we identified a novel BRAF mutation, N581I, in a
vulval melanoma. Mutation involving the same codon but
with a different amino acid substitution (N581S, previously
N580S) has been reported in a single case of colorectal
Figure 1 Sequence chromatograms showing (A) wild-type sequence in
codon 600 in a malignant melanoma of soft parts; (B) the T1799A
(V600E) (arrow) mutation in a malignant melanoma of the nasopharynx;
and (C) the A1742T (N581I) (arrow) mutation in a malignant melanoma
of the vulva.
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cancer.29 The pathogenic relevance of this novel BRAF
mutation awaits further functional characterisation.
NRAS mutation was found in five of 36 mucosal
melanomas. This is also comparable to a previous study,
which recorded NRAS mutations in four of 28 mucosal
melanomas.30 In our present study, BRAF and NRAS
mutations were mutually exclusive; thus, overall seven of
the 36 mucosal melanomas had activation of the RAS–RAF–
MEK–ERK–MAPK pathway through either BRAF or NRAS
mutation. To our knowledge, this is the first comprehensive
study that has characterised both BRAF and NRAS mutations
in mucosal melanomas. The combined incidence of BRAF
and NRAS mutations is significantly lower (p , 0.0001) than
that seen in cutaneous melanomas (table 2).
We found a complete absence of BRAF or NRAS mutations
in the seven malignant melanomas of soft parts, which
is significantly different from cutaneous melanomas
(p , 0.0001). This is the first systematic study of BRAF
and NRAS mutation for this type of melanoma. Malignant
melanoma of soft parts constitutes a distinct subgroup of
malignant melanoma with an intriguing histiogenesis and
molecular pathway of tumour development.4 5 These tumours
tend to occur in deep tendons and aponeuroses, where
melanocytes are not known to exist normally, and there is no
involvement of the overlying skin. They have the same
immunohistochemical profile as cutaneous melanomas—
expressing the melanocytic markers HMB45 and S100
protein—the latter highlighting their neural crest origin.
Intracellular melanin, although scanty, can be demonstrated
in more than 50% of cases. The prognosis is generally poor,
with a high propensity for recurrence and metastasis.
Recurrence may sometimes occur after a long latent period
of 10 or more years. The characteristic genetic change in these
tumours is the t(12;22)(q13;q12) translocation, resulting in
the expression of a fusion EWS–ATF1 transcript, which has
not been found in cutaneous melanoma. In this respect,
translocation involving the EWS gene is also involved in the
development of several sarcomas, including Ewing’s sarcoma
and primitive neuroectodermal tumour. BRAF mutations are
extremely rare in sarcoma, and were seen in only one of 182
(0.5%) cases in our previous mutation screening.9 The rarity
of BRAF or NRAS mutations in malignant melanoma of soft
parts and the common occurrence of translocation involving
the EWS gene suggest that this tumour is more closely
related to sarcoma than cutaneous melanoma in its onco-
genetic pathway. Interestingly, both BRAF and the EWS–
ATF1 fusion gene are involved at different points along the
cAMP responsive pathway, which plays an important role in
regulating the differentiation and melanogenesis of melano-
cytes.31–35 Whereas BRAF mediates the cAMP dependent
activation of ERKs in melanocytes,36 the EWS–ATF1 chimae-
ric protein can function as a potent constitutive activator of
several cAMP inducible promoters.37 38 It would be interesting
to study whether the EWS–ATF1 fusion gene product and
mutant BRAF have similar biological roles in melanoma
oncogenesis, which could help to explain the absence of
BRAF mutations in malignant melanoma of soft parts.
‘‘The difference in incidence of BRAF mutations in different
subtypes of melanoma could be related to aetiological
factors such as ultraviolet exposure’’
The difference in the incidence of BRAF mutation among
different subtypes of malignant melanomas is intriguing.
BRAF mutation appears to play an important role in
regulating the growth of melanocytes and malignant
transformation in the cutaneous compartment. Up to 80%
of benign naevi of various histological types, including
compound naevi, junctional naevi, and congenital naevi,
harbour BRAF mutations.12 However, it should be noted that
most benign naevi are end stage lesions and do not progress
to malignant melanoma. In contrast, a study of cutaneous
melanoma revealed a low incidence of BRAF mutation (10%)
at the radial growth phase, but a high incidence (63%) in the
vertical growth phase, which suggests that BRAF mutation
does not occur at the initiation of tumorigenesis but is
important in the progression of cutaneous melanoma.10 It has
been suggested that the difference in incidence of BRAF
mutations in different subtypes of melanoma could be related
to aetiological factors such as UV exposure. Accumulating
data, including those from the current series, show that the
highest incidence of BRAF mutation is found in melanoma
that develops in skin subjected to intermittent sun expo-
sure.20 Melanoma developing in skin with chronic sun
damage, in glabrous skin shielded from UV by the cornified
layer, and in mucosa totally protected from UV exposure
generally has a low incidence of BRAF mutation, in the range
of 0–15%.18–20 Uveal melanoma and, in this series, melanoma
of soft parts do not show BRAF mutation at all.14–17 In
contrast, a higher incidence of NRAS mutation was seen in
melanoma arising from skin with continuous sun exposure
than in skin with intermittent sun exposure or sun protected
mucosa.6 8 30 39 Although the mutation spectrum in NRAS in
many of the cutaneous melanomas is compatible with UV
induced mutations—with a hotspot mutation site in codon
Table 2 Differences in incidence of BRAF or BRAF/NRAS mutations in various types of non-cutaneous melanomas (present
study) compared with primary cutaneous melanomas (from the literature)
Melanoma type Incidence of BRAF mutation p Value*
Combined incidence of BRAF/NRAS
mutations p Value*
Primary cutaneous melanoma 178/444 (40.1%)10 12 15 18 20 22–28 111/141 (78.7%)10 22–24 28
Malignant melanoma of soft parts 0/7 (0%) 0.029 0/7 (0%) ,0.0001
Mucosal melanomas 2/36 (5.6%) ,0.0001 7/36 (19.4%) ,0.0001
Uveal melanomas 0/6 (0%) 0.048 1/6 (16.7%) 0.0029
All non-cutaneous melanomas 2/51 (3.9%) ,0.0001 9/51 (17.6%) ,0.0001
*Comparison of each category against primary cutaneous melanomas using Fisher’s exact test.
Literature data were pooled from the references.
Take home messages
N In contrast to cutaneous melanoma, we found a low
incidence of BRAF and NRAS mutations in mucosal
melanoma arising from the aerodigestive and female
genital tracts, and a complete lack of these mutations in
malignant melanoma of soft parts
N Each subtype of melanoma may have its own unique
genetic pathway of development, and only a small
proportion of patients with non-cutaneous melanoma
may benefit from anti-RAF specific treatment
BRAF mutations in non-cutaneous melanomas 643
www.jclinpath.com
 on 8 November 2006 jcp.bmj.comDownloaded from 
61 involving a TT pyrimidine doublet and its 39 nucleotide—
the most frequent hotspot mutation of BRAF involves a T to A
mutation, which is not typical of UV induced mutation.
Moreover, a similar mutation spectrum for NRAS genes was
found in some of the melanomas arising from internal
organs, which are clearly not related to UV exposure. Thus,
other environmental or intrinsic biological factors should also
be considered as potential causative agents for these
mutations in melanomas.
In summary, we have documented a low incidence of
BRAF and NRAS mutation in mucosal melanoma arising
from the aerodigestive and female genital tracts. Moreover,
BRAF and NRAS mutation are totally absent in malignant
melanoma of soft parts. These data suggest that each subtype
of melanoma may have its own unique genetic pathway of
development, and only a small proportion of patients with
non-cutaneous melanoma may benefit from anti-RAF spe-
cific treatment.
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